Medication Management Consultancy

By Dementia Training Australia

  • Enhanced Practice
  • 4 months
  • Blended: Online Course and Virtual Classroom
Access on dta.com.au

There is a growing awareness of the potential over and inappropriate use of psychotropic medications, such as antipsychotics and other sedatives, in older people, especially those with dementia. This consultancy service that assists residential care providers to ensure that their use of antipsychotic medications is aligned with recommended practice. The Medication Management Consultancy consists of: • Benchmarking before and after the Consultancy service to measure staff knowledge about recommended use of antipsychotic and other psychotropic medications for changed behaviours and the number of residents prescribed antipsychotic medications for changed behaviours. • Resources including Antipsychotic Tracking Tool, handheld quick reference cards, reminder stickers and poster, fact sheets about antipsychotic and psychotropic medications, comprehensive participant guides, and email template to inform prescribers about consultancy. • Minimising use of antipsychotic medications for responsive behaviour: 1.5 hour online course. • Appropriate use of benzodiazepines and other sedatives: 4 hours optional online course. • Virtual Classroom Session focusing on Behaviour Assessment Plan/Behaviour Support Plan and how to safely start and stop antipsychotic medications. • Support for staff through regular virtual meetings with a DTA Consultant and nominated staff to work through a change process and develop personalised plans

Domains:
Behaviour

Location:
nationally

Cost:

Learning Outcomes

The objectives of the consultancy include:
  • Ensure chemical restraints are used only as a last resort after all other best practice behaviour supports have failed.
  • Minimise the number of antipsychotic and other psychotropic medications prescribed for responsive behaviours.
  • Enhance staff knowledge regarding the use of antipsychotic and other psychotropic medications for responsive behaviours.
  • Development of a sustainable process that guides the responsible use of antipsychotic and other psychotropic medications in the future.